0001437749-26-017045
SEC filingImmuCell delivered robust Q1 results with 28% revenue growth to $10.4M and exceptional margin expansion to 45% gross and 19% operating, driving $1.9M net income and $3.4M free cash flow through strong product demand and operational leverage.
ImmuCell's revenue surged 28% year-over-year to $10.4M in Q1 FY2026, primarily due to higher sales volumes of Tri-Shield® and Dual Force® mastitis treatments combined with price increases across most product lines. This reflects sustained demand in the animal health sector, particularly during Q1 calving peaks in dairy operations, enabling topline acceleration while enhancing gross margins through favorable product mix and pricing power. The growth underscores ImmuCell's competitive positioning in bovine immunology products.
Recent Exhibit 10.1 employment agreements, including for CFO Timothy C. Fiori, underscore executive retention efforts amid strong results. Filings note no material changes to prior risk factors but caution on unanticipated developments in product development or markets. Robust cash generation equips ImmuCell to address uncertainties in the animal health landscape.